FDA approval puts Numelvi into the canine itch market: full analysis

A new canine dermatology drug has arrived at a sensitive moment for the antipruritic market. On February 25, 2026, the FDA approved NUMELVI, Merck Animal Health’s atinvicitinib tablets, for the control of pruritus associated with allergic dermatitis in dogs 6 months of age and older, giving veterinarians a new once-daily oral option for one of the most common reasons dogs present in practice. Merck says the product will be available to U.S. veterinary clinics and hospitals in spring 2026. (merck.com)

The backdrop matters. The veterinary JAK inhibitor category was already active before this approval, led by Zoetis’ Apoquel and then reshaped by Elanco’s Zenrelia, which won FDA approval in September 2024 for allergic dermatitis-associated pruritus and atopic dermatitis in dogs at least 12 months old. But Zenrelia’s launch came with unusually prominent label discussion around vaccine response after FDA reported inadequate immune responses in some treated dogs and fatal vaccine-induced disease in a study setting, making vaccine timing a practical and reputational issue for clinics. Elanco’s current product information says fatal vaccine-induced disease language was removed from the U.S. label in September 2025, but the earlier FDA warning helped frame the market NUMELVI is now entering. (fda.gov)

Merck is clearly trying to differentiate on both mechanism and use profile. In its approval announcement, the company described NUMELVI as the first and only second-generation JAK inhibitor in veterinary medicine for this indication, and dvm360’s coverage highlighted company claims that the drug is at least 10 times more selective for JAK1 than for JAK2, JAK3, and TYK2. Merck also says most dogs starting at 4.4 pounds require only one or half of a tablet, and that there is no need to adjust vaccination schedules, messaging that appears designed to resonate with both general practice teams and dermatology specialists managing long-term allergic disease. (merck.com)

Regulatory documents give that vaccine point more substance. The FDA’s approval summary for NUMELVI states that dogs given atinvicitinib at three times the intended maximum labeled dose for 84 days did not show interference with the ability of core vaccines to induce protective immune responses. That is likely to be one of the most closely watched details as the product rolls out, because it addresses a question that has become front-of-mind for veterinarians after the Zenrelia experience. NUMELVI is approved for younger dogs than Zenrelia as well, which may broaden its relevance in first-opinion practice where allergic signs often emerge well before a dog’s first birthday. (animaldrugsatfda.fda.gov)

Early commentary has reflected that positioning. In Merck’s announcement, Christine McKinney, DVM, DACVD, senior professional services veterinarian at Merck Animal Health, said the product could improve quality of life by reducing chronic itching and the downstream chewing, licking, scratching, skin damage, infections, pain, and sleep disruption that follow. dvm360’s coverage also tied the launch to caregiver burden, noting that skin cases can account for a substantial share of daily canine caseload in general practice. Those are company and trade-publication perspectives rather than independent post-market assessments, but they align with the practical reality that itch control is both a medical and relationship issue in small animal practice. (merck.com)

That practical reality extends beyond pharmacology. Chronic dermatology cases often become conversations about repeat visits, secondary infections, long-term medication costs, and whether clients can say yes to the plan in front of them. That broader context has been showing up across veterinary trade coverage lately, from advice on how to discuss pet insurance more productively with clients to new payment-reimbursement partnerships such as Synchrony’s expansion with Figo and Embrace, which are meant to reduce payment friction after CareCredit use. None of that changes NUMELVI’s label, but it does shape how quickly a new chronic-use product can move from interest to actual adherence in exam-room use. (todaysveterinarybusiness.com)

Why it matters: For veterinary professionals, NUMELVI’s significance is competitive, clinical, and operational. Competitive, because another branded oral antipruritic entrant could affect pricing, formulary choices, and how practices discuss options with pet parents. Clinical, because the younger age indication and vaccine-response data may make the product attractive in cases where veterinarians want an oral option but have hesitated around timing, label restrictions, or immune-response questions. Operational, because dermatology appointments often involve repeated follow-up, secondary infections, and client frustration; a product that is easy to dispense, simple to dose, and easier to explain could improve adherence as much as it improves itch scores. Those benefits still need to be tested in everyday practice, but they’re the pressure points most likely to drive adoption. (merck.com)

There’s also a broader market signal here. Merck had already secured a positive opinion from the European Medicines Agency’s Committee for Veterinary Medicinal Products in June 2025, suggesting the company was building toward a global dermatology play before the U.S. approval landed. That matters because canine dermatology remains one of the largest chronic-care segments in companion animal medicine, and manufacturers increasingly see room to compete not just on efficacy, but on age range, safety framing, convenience, and how well a label fits real clinic workflows. At the same time, the profession is paying closer attention to the systems around care delivery, from technician utilization and scope-of-practice debates to continuing education and specialist training pipelines. Those trends do not determine whether NUMELVI works, but they do influence how efficiently practices can absorb and support another chronic-care option. (ema.europa.eu)

That last point is easy to overlook. Veterinary medicine’s research and training pipeline continues to generate clinically relevant work, including residency research on diagnostics and chronic neurologic and infectious disease questions that may eventually affect everyday case management. In parallel, technician-focused initiatives such as NAVTA’s new scope-of-practice report and its collaboration with Fear Free reflect a profession still trying to improve staffing sustainability, patient handling, and team efficiency. For practices managing high-volume skin caseloads, those operational factors can matter almost as much as the arrival of a new branded tablet. (todaysveterinarybusiness.com)

What to watch: Over the next several months, watch for launch timing and stocking patterns in U.S. clinics, any publication of peer-reviewed efficacy or safety data beyond company materials, and whether independent dermatologists validate Merck’s vaccine-schedule and selectivity narrative in day-to-day use. The bigger question is whether NUMELVI becomes a niche alternative or quickly establishes itself as a first-line option for dogs with allergic itch, especially younger patients and those whose treatment plans intersect with routine vaccination. Just as important, watch whether its convenience and safety framing hold up in the real-world setting that actually determines uptake: busy practices balancing cost conversations, technician workflows, and long-term client follow-through. (merck.com)